Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
-
Antineoplastic Combined Chemotherapy Protocols
-
Antineoplastic Combined Chemotherapy Protocols
-
Cytarabine
-
Cytarabine
-
Drug Monitoring
-
Drug Monitoring
-
Female
-
Female
-
Humans
-
Humans
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Leukemia, Myeloid, Acute
-
Leukemia, Myeloid, Acute
-
Male
-
Male
-
Maximum Tolerated Dose
-
Maximum Tolerated Dose
-
Methemoglobinemia
-
Methemoglobinemia
-
Middle Aged
-
Middle Aged
-
Pyridines
-
Pyridines
-
Recurrence
-
Recurrence
-
Thiosemicarbazones
-
Thiosemicarbazones